Loading
A phase 1/2 trial of IN10018, Tislelizumab, Carboplatin in small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.
IN10018 Combination Therapy in Treatment-naïve ES-SCLC is a phase 1/2 interventional study registered as NCT06030258 by InxMed (Shanghai) Co., Ltd., with 120 participants planned, started 2023-10-30 and due to reach its primary completion in 2025-12-24. Interventions recorded: IN10018, Tislelizumab, Carboplatin, Etoposide. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tislelizumab, Extensive-stage small-cell lung cancer, Etoposide, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/